Skip to main content
SpringerLink
Log in

Medical Treatment of Perianal Crohn’s Disease Fistulae

  • Chapter
  • First Online:
Pediatric Inflammatory Bowel Disease

  • 1091 Accesses

Abstract

Inflammatory bowel disease can be characterized as inflammatory, stricturing, and penetrating/fistulizing disease. Perianal disease involving fistulae and abscess are common and important aspect of this disease, and require effective therapy. The treatment of perianal CD fistulae has improved greatly over the last 15 years as new medical therapies, especially infliximab, have been developed. The purpose of this chapter is to discuss our current knowledge of perianal fistulizing CD, focusing on its medical management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity. JAMA. 1932;99:1323–9.

    Article  Google Scholar 

  2. Bissell AD. Localized chronic ulcerative colitis. Ann Surg. 1934;99:957–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. American Gastroenterological Association. American Gastroenterological Association medical position statement: perianal Crohn’s disease. Gastroenterology. 2003;125:1503–7.

    Article  Google Scholar 

  4. American Gastroenterological Association. AGA technical review on perianal Crohn’s disease. Gastroenterology. 2003;125:1508–30.

    Article  Google Scholar 

  5. Scott HJ, Northover JM. Evaluation of surgery for perianal Crohn’s fistulas. Dis Colon Rectum. 1996;39:1039–43.

    Article  CAS  PubMed  Google Scholar 

  6. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis. 2003;9:98–103.

    Article  PubMed  Google Scholar 

  7. Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rates in fistulizing anorectal Crohn’s disease: a single center experience. Dis Colon Rectum. 2003;46:577–83.

    Article  PubMed  Google Scholar 

  8. Bell SJ, Williams AB, Wiesel P, Wilkinson K, Cohen RC, Kamm MA. The clinical course of fistulating Crohn’s disease. Aliment Pharmacol Ther. 2003;17:1145–51.

    Article  CAS  PubMed  Google Scholar 

  9. Schwartz DA, Herdman CR. Review article: the medical treatment of Crohn’s perianal fistulas. Aliment Pharmacol Ther. 2004;19:953–67.

    Article  CAS  PubMed  Google Scholar 

  10. Hughes L. Surgical pathology and management of anorectal Crohn’s disease. J R Soc Med. 1978;71:644–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Parks A. The pathogenesis and treatment of fistula-in-ano. Br Med J. 1961;1:463–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Fielding JF. Perianal lesions in Crohn’s disease. J R Coll Surg Edinb. 1972;17:32–7.

    CAS  PubMed  Google Scholar 

  13. Greenstein AJ, Kark AE, Drelling DA. Crohn’s disease of the colon I. Fistula in Crohn’s disease colon, classification presenting features and management in 63 patients. Am J Gastroenterol. 1974;62:419–29.

    CAS  PubMed  Google Scholar 

  14. Farmer R, Hawk W, Turnbull RJ. Clinical patterns in Crohn’s disease. A statistical study of 615 cases. Gastroenterology. 1975;68:627–35.

    CAS  PubMed  Google Scholar 

  15. Rankin GB, Watts HD, Melnyk CS, Kelley Jr ML. National Cooperative Crohn’s Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology. 1979;77:914–20.

    CAS  PubMed  Google Scholar 

  16. Buchmann P, Keighly MR, Allan RN, Thompson H, Alexander-Williams J. Natural history of perianal Crohn’s disease. Ten year follow-up: a plea for conservatism. Am J Surg. 1980;140:642–4.

    Article  CAS  PubMed  Google Scholar 

  17. Williams DR, Coller JA, Corman ML, Nugent FW, Veidenheimer MC. Anal complications in Crohn’s disease. Dis Colon Rectum 1981;24:22–4.

    Google Scholar 

  18. Marks CG, Ritchie JK, Lockhart-Mummery HE. Anal fistulas in Crohn’s disease. Br J Surg. 1981;68:525–7.

    Article  CAS  PubMed  Google Scholar 

  19. Hobbiss JH, Schofield PF. Management of perianal Crohn’s disease. J R Soc Med. 1982;75:414–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Van Dongen LM, Lubbers E. Perianal fistulas in patients with Crohn’s disease. Arch Surg. 1986;121:1187–90.

    Article  CAS  PubMed  Google Scholar 

  21. Goebell H. Perianal complications in Crohn’s disease. Neth J Med. 1990;37:S47–51.

    PubMed  Google Scholar 

  22. Hellers G, Bergstrand O, Ewerth S, Homstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease. Gut. 1980;21:525–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Schwartz DA, Loftus EV, Tremaine WJ, Pananccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of fistulizing Crohn’s disease in Olmstead County, Minnesota. Gastroenterology. 2002;122:875–80.

    Article  PubMed  Google Scholar 

  24. Gray BK, Lockhart-Mummery HE, Morson BC. Crohn’s disease of the anal region. Gut. 1965;6:515–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Halme L, Sainio AP. Factors related to frequency, type, and outcome of anal fistulas in Crohn’s disease. Dis Colon Rectum. 1995;38:55–9.

    Article  CAS  PubMed  Google Scholar 

  26. Judge TA, Lichtenstein GR. Treatment of fistulizing Crohn’s disease. Gastroenterol Clin N Am. 2004;33:421–54.

    Article  Google Scholar 

  27. Bayer I, Gordon PH. Selected operative management of fistula-in-ano in Crohn’s disease. Dis Colon Rectum. 1994;37:760–5.

    Article  CAS  PubMed  Google Scholar 

  28. Makowiec F, Jehle EC, Becker HD, Starlinger M. Perianal abscess in Crohn’s disease. Dis Colon Rectum. 1997;40:443–50.

    Article  CAS  PubMed  Google Scholar 

  29. Van Beers B, Grandin C, Kartheuser A. MRI of complicated anal fistulae: comparison with digital examination. J Comput Assist Tomogr. 1994;18:87–90.

    Article  CAS  PubMed  Google Scholar 

  30. Fazio VW, Wilk P, Turnbull Jr RB, Jagelman DG. The dilemma of Crohn’s disease: ileosigmoidal fistula complicating Crohn’s disease. Dis Colon Rectum. 1977;20:381–6.

    Article  CAS  PubMed  Google Scholar 

  31. Kuijpers HC, Schulpen T. Fistulography for fistula-in-ano. Is it useful? Dis Colon Rectum. 1985;28:103–4.

    Article  CAS  PubMed  Google Scholar 

  32. Glass RE, Ritchie JK, Lennard-Jones JE, Hawley PR, Todd IP. Internal fistulas in Crohn’s disease. Dis Colon Rectum. 1985;28:557–61.

    Article  CAS  PubMed  Google Scholar 

  33. Pomerri F, Pittarello F, Dodi G, Pianon P, Muzzio PC. Radiologic diagnosis of anal fistulae with radio-opaque markers. Radiol Med. 1988;75:632–7.

    CAS  PubMed  Google Scholar 

  34. Weisman RI, Orsay CP, Pearl RK, Abcarian H. The role of fistulography in fistula-in-ano. Report of five cases. Dis Colon Rectum. 1991;34:181–4.

    Article  CAS  PubMed  Google Scholar 

  35. Berliner L, Redmond P, Purow E, Megna D, Scottile V. Computed tomography in Crohn’s disease. Am J Gastroenterol. 1982;77:584–53.

    Google Scholar 

  36. Goldberg HI, Gore RM, Margulis AR, Moss AA, Baker EL. Computed tomography in the evaluation of Crohn’s disease. Am J Roentgenol. 1983;140:277–82.

    Article  CAS  Google Scholar 

  37. Kerber GW, Greenberg M, Rubin JM. Computed tomography evaluation of local and extraintestinal complications of Crohn’s disease. Gastrointest Radiol. 1984;9:143–8.

    Article  CAS  PubMed  Google Scholar 

  38. Fishman EK, Wolf EJ, Jones B, Bayless TM, Siegelman SS. CT evaluation of Crohn’s disease: effect on patient management. Am J Roentgenol. 1987;148:537–40.

    Article  CAS  Google Scholar 

  39. Yousem DM, Fishman EK, Jones B. Crohn’s disease: perirectal and perianal findings at CT. Radiology. 1988;167:331–4.

    Article  CAS  PubMed  Google Scholar 

  40. Van Outryve MJ, Pelckmans PA, Michielsen PP, Van Maercke YM. Value of tranrectal ultrasonography in Crohn’s disease. Gastroenterology. 1991;101:1171–7.

    Article  CAS  PubMed  Google Scholar 

  41. Schratter-Sehn AU, Lochs H, Vogelsang H, Schurawitzki H, Herold C, Schratter M. Endoscopic ultrasonography versus computed tomography in the differential diagnosis of perianorectal complications in Crohn’s disease. Endoscopy. 1993;25:582–6.

    Article  CAS  PubMed  Google Scholar 

  42. Koelbel G, Schmiedl U, Majer MC, Weber P, Jenss H, Kueper K, Hess CF. Diagnosis of fistulae and sinus tracts in patients with Crohn’s disease: value of MR imaging. Am J Roentgenol. 1989;152:999–1003.

    Article  CAS  Google Scholar 

  43. Skalej M, Makowiec F, Weinlich M, Jenss H, Laniado M, Starlinger M. Magnetic resonance imaging in perianal Crohn’s disease. Dtsch Med Wochenschr. 1993;118:1791–6.

    Article  CAS  PubMed  Google Scholar 

  44. Lunniss PJ, Barker PG, Sultan AH, Armstrong P, Reznek RH, Bartram CI, Cottam KS, Phillips RK. Magnetic resonance imaging of fistula-in-ano. Dis Colon Rectum. 1994;37:708–18.

    Article  CAS  PubMed  Google Scholar 

  45. Barker PG, Lunniss PJ, Armstrong P, Reznek RH, Cottam KS, Phillips RK. Magnetic resonance imaging of fistula-in-ano: technique, interpretation, and accuracy. Clin Radiol. 1994;49:7–13.

    Article  CAS  PubMed  Google Scholar 

  46. Haggert PJ, Moore NR, Shearman JD, Travis SP, Jewell DP, Mortensen NJ. Pelvic and perianal complications of Crohn’s disease: assessment using magnetic resonance imaging. Gut. 1995;36:407–10.

    Article  Google Scholar 

  47. DeSouza NM, Hall AS, Puni R, Gilderdale DJ, Young IR, Kmiot WA. High resolution magnetic resonance imaging of the anal sphincter using a dedicated endoanal coil. Comparison of magnetic resonance imaging with surgical finding. Dis Colon Rectum. 1996;39:926–34.

    Article  CAS  PubMed  Google Scholar 

  48. Spencer JA, Chapple K, Wilson D, Ward J, Windsor AC, Ambrose NS. Outcome after surgery for perianal fistula: predictive value of MR imaging. Am J Roentgenol. 1998;171:403–6.

    Article  CAS  Google Scholar 

  49. Schwartz DA, Wiersema MJ, Dudiak KM, Fletcher JG, Clain JE, Tremaine WJ, Zinsmeister AR, Norton ID, Boardman LA, Devine RM, Wolff BG, Young-Fadok TM, Diehl NN, Pemberton JH, Sandborn WJ. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn’s perianal fistulas. Gastroenterology. 2001;121:1064–72.

    Article  CAS  PubMed  Google Scholar 

  50. Beets-Tan RG, Beets GL, van der Hoop AG, Kessels AG, Vliegen RF, Baeten CG, van Engelshoven JM. Preoperative MR imaging of anal fistulas: does it really help the surgeon? Radiology. 2001;218:75–84.

    Article  CAS  PubMed  Google Scholar 

  51. Tio TL, Mulder CJ, Wijers OB, Sars PR, Tytgat GN. Endosonography of peri-anal and per-colorectal fistula and/or abscess in Crohn’s disease. Gastrointest Endosc. 1990;36:331–6.

    Article  CAS  PubMed  Google Scholar 

  52. Wijers O, Tio T, Tytgat G. Endosonography (transrectal and transvaginal) in the assessment of perianorectal fistulas and abscesses: experience with 127 cases. In: Demling L, Fruhmorgan P, editors. Non-neoplastic diseases of the anorectum. London: Kluwer; 1992. p. 65–78.

    Google Scholar 

  53. Solomon MJ. Fistulae and abscesses in symptomatic perianal Crohn’s disease. Int J Color Dis. 1996;11:222–6.

    Article  CAS  Google Scholar 

  54. Orsoni P, Barthet M, Portier F, Panuel M, Desjeux A, Grimaud JC. Prospective comparison of endosonography, magnetic resonance imaging and surgical findings in anorectal fistula and abscess complicating Crohn’s disease. Br J Surg. 1999;86:360–4.

    Article  CAS  PubMed  Google Scholar 

  55. Stewart LK, McGee J, Wilson SR. Transperineal and transvaginal sonography of perianal inflammatory bowel disease. Am J Roentgenol. 2001;177:627–32.

    Article  CAS  Google Scholar 

  56. Sloots CE, Felt-Bersma RJ, Poen AC, Cuesta MA, Meuwissen SG. Assessment and classification of fistula-in-ano in patients with Crohn’s disease by hydrogen peroxide enhanced transanal ultrasound. Int J Color Dis. 2001;16:292–7.

    Article  CAS  Google Scholar 

  57. Sparberg M, Kirsner JB. Long-term corticosteroid therapy for regional enteritis: an analysis of 58 courses in 54 patients. Am J Dig Dis. 1966;11:865–80.

    Article  CAS  PubMed  Google Scholar 

  58. Jones JH, Lennard-Jones JF. Corticosteroids and corticotropin in the treatment of Crohn’s disease. Gut. 1966;7:181–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Agrawal A, Durrani S, Leiper K, Ellis A, Morris AI, Rhodes JM. Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn’s disease. Clin Gastroenterol Hepatol. 2005;3:1215–20.

    Article  CAS  PubMed  Google Scholar 

  60. Ursing B, Kamme C. Metronidazole for Crohn’s disease. Lancet. 1975;1:775–7.

    Article  CAS  PubMed  Google Scholar 

  61. Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perianal Crohn’s disease with metronidazole. Gastroenterology. 1980;79:357–65.

    CAS  PubMed  Google Scholar 

  62. Schneider MU, Strobel S, Riemann JF, Demling L. Treatment of Crohn’s disease with metronidazole. Dtsch Med Wochenschr. 1981;106:1126–9.

    Article  CAS  PubMed  Google Scholar 

  63. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perianal Crohn’s disease: a follow-up study. Gastroenterology. 1982;83:383–7.

    CAS  PubMed  Google Scholar 

  64. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol. 1984;79:533–40.

    CAS  PubMed  Google Scholar 

  65. Schneider MU, Laudage G, Guggenmoos-Holzmann I, Riemann JF. Metronidazole in the treatment of Crohn’s disease. Results of a controlled randomized prospective study. Dtsch Med Wochenschr. 1985;110:1724–30.

    Article  CAS  PubMed  Google Scholar 

  66. Turunen U, Farkkila M, Seppala K. Long-term treatment of perianal or fistulous Crohn’s disease with ciprofloxacin. Scand J Gastroenterol Suppl. 1989;24:144.

    Google Scholar 

  67. Wolf JL. Ciprofloxacin may be useful in Crohn’s disease (abstr). Gastroenterology. 1990;98:A212.

    Google Scholar 

  68. Solomon MJ, McLeod RS, O’Connor BI, Steinhart AH, Greenberg GR, Cohen Z. Combination ciprofloxacin and metronidazole in severe perianal Crohn’s disease. Can J Gastroenterol. 1993;7:571–3.

    Article  Google Scholar 

  69. Turunen U, Farkkila M, Valtonen V. Long-term outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn’s disease (abstr). Gastroenterology. 1993;104:A793.

    Google Scholar 

  70. Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs. 1997;54:679–708.

    Article  CAS  PubMed  Google Scholar 

  71. Davis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs. 1996;51:1019–74.

    Article  CAS  PubMed  Google Scholar 

  72. Casparian JM, Luchi M, Moffat RE, Hinthorn D. Quinolones and tendon ruptures. South Med J. 2000;93:488–91.

    Article  CAS  PubMed  Google Scholar 

  73. Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, Bernstein CN, Sandborn WJ. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn’s disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009;15:17–24.

    Article  PubMed  Google Scholar 

  74. Brooke BN, Hoffman DC, Swarbrick ET. Azathioprine for Crohn’s disease. Lancet. 1969;2:612–4.

    Article  CAS  PubMed  Google Scholar 

  75. Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn’s disease. Lancet. 1971;2:944–7.

    Article  CAS  PubMed  Google Scholar 

  76. Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn’s disease. Lancet. 1971;2:1273–6.

    Article  CAS  PubMed  Google Scholar 

  77. Klein M, Binder HJ, Mitchell M, Aaronson R, Spiro H. Treatment of Crohn’s disease with azathioprine: a controlled evaluation. Gastroenterology. 1974;66:916–22.

    CAS  PubMed  Google Scholar 

  78. Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn’s disease. Am J Digest Dis. 1975;20:721–6.

    Article  CAS  PubMed  Google Scholar 

  79. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302:981–7.

    Article  CAS  PubMed  Google Scholar 

  80. Pearson D, May G, Fick G, Sutherland L. Azathioprine and 6-mercaptopurine in Crohn’s disease: a meta analysis. Ann Intern Med. 1995;123:132–42.

    Article  CAS  PubMed  Google Scholar 

  81. Korelitz BI, Present DH. Favorable effect of mercaptopurine on fistulae of Crohn’s disease. Digest Dis Sci. 1985;30:58–64.

    Article  CAS  PubMed  Google Scholar 

  82. Jeshion WC, Larsen KL, Jawad AF, Piccoli DA, Verma R, Maller ES, Baldassano RN. Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn’s disease in children. J Clin Gastroenterol. 2000;30:294–8.

    Article  CAS  PubMed  Google Scholar 

  83. Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease. Aliment Pharmacol Ther. 2003;18:1113–20.

    Article  CAS  PubMed  Google Scholar 

  84. Arseneau KO, Cohn SM, Cominelli F, Connors Jr AF. Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology. 2001;120:1640–56.

    Article  CAS  PubMed  Google Scholar 

  85. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006;130:1047–53.

    Article  CAS  PubMed  Google Scholar 

  86. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641–9.

    Article  CAS  PubMed  Google Scholar 

  87. Dayharsh GA, Loftus Jr EV, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, Macon WR, Burgart LJ. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002;122:72–7.

    Article  CAS  PubMed  Google Scholar 

  88. Vandeputte L, D’Haens G, Beart F, Rutgeerts P. Methotrexate in refractory Crohn’s disease. Inflamm Bowel Dis. 1999;5:11–5.

    Article  CAS  PubMed  Google Scholar 

  89. Mahadevan U, Marion JF, Present DH. Fistula response to methotrexate in Crohn’s disease: a case series. Aliment Pharmacol Ther. 2003;18:1003–8.

    Article  CAS  PubMed  Google Scholar 

  90. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91:423–33.

    CAS  PubMed  Google Scholar 

  91. Lemann M, Zenjari T, Bouhnik Y, Cosnes J, Mesnard B, Rambaud JC. Methotrexate in Crohn’s disease: long-term efficacy and toxicity. Am J Gastroenterol. 2000;95:1730–4.

    CAS  PubMed  Google Scholar 

  92. Fukushima T, Sugita A, Masuzawa S, Yamazaki Y, Tsuchiya S. Effects of cyclosporine A on active Crohn’s disease. Gastroenterol Jpn. 1989;24:12–5.

    CAS  PubMed  Google Scholar 

  93. Lichtiger S. Cyclosporin therapy in inflammatory bowel disease: open-label experience. Mt Sinai J Med. 1990;57:315–9.

    CAS  PubMed  Google Scholar 

  94. Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn’s disease. Gastroenterology. 1990;99:1347–51.

    Article  CAS  PubMed  Google Scholar 

  95. Hanauer SB, Smith MB. Rapid closure of Crohn’s disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol. 1993;88:646–9.

    CAS  PubMed  Google Scholar 

  96. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn’s disease. Dig Dis Sci. 1994;39:374–80.

    Article  CAS  PubMed  Google Scholar 

  97. Abreu-Martin J, Vasilauskas E, Gaiennie J, Voigt B, Targan SR. Continuous infusion cyclosporine is effective for acute severe Crohn’s disease...but for how long (abstr)? Gastroenterology. 1996;110:A851.

    Google Scholar 

  98. O’Neill J, Pathmakanthan S, Goh J, Costello S, MacMathuna P, O’Connell R, Crowe J, Lennon J. Cyclopsorine A induces remission in fistulous Crohn’s disease but relapses occur upon cessation of treatment (abstr). Gastroenterology. 1997;112:A1056.

    Article  Google Scholar 

  99. Hinterleitner TA, Petritsch W, Aichbichler B, Fickert P, Ranner G, Krejs GJ. Combination of cyclosporine, azathioprine and prednisone for perianal fistulas in Crohn’s disease. Z Gastroenterol. 1997;35:603–8.

    CAS  PubMed  Google Scholar 

  100. Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn’s disease with intravenous cyclosporine. Am J Gastroenterol. 1998;93:442–8.

    Article  CAS  PubMed  Google Scholar 

  101. Gurudu SR, Griffel LH, Gialanella RJ, Das KM. Cyclosporine therapy in inflammatory bowel disease: short- and long-term results. J Clin Gastroenterol. 1999;29:151–4.

    Article  CAS  PubMed  Google Scholar 

  102. Present DH. Crohn’s fistula: current concepts in management. Gastroenterology. 2003;124:1629–35.

    Article  PubMed  Google Scholar 

  103. Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis. 1995;1:48–63.

    Google Scholar 

  104. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn’s disease. Am J Gastroenterol. 1997;92:876–9.

    CAS  PubMed  Google Scholar 

  105. Fellerman K, Ludwig D, Stahl M, David-Walek T, Stange EF. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol. 1998;93:1860–6.

    Article  Google Scholar 

  106. Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn’s disease perianal fistulae. Inflamm Bowel Dis. 1999;5:239–45.

    Article  CAS  PubMed  Google Scholar 

  107. Ierardi E, Principi M, Rendina M, Francavilla R, Ingrosso M, Pisani A, Amoruso A, Panella C, Francavilla A. Oral tacrolimus (FK506) in Crohn’s disease complicated by fistulae of the perineum. J Clin Gastroenterol. 2000;125(30):200–2.

    Article  Google Scholar 

  108. Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, Sandler RS. Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology. 2003;125:380–8.

    Article  CAS  PubMed  Google Scholar 

  109. Gonzalez-Lama Y, Abreu L, Vera MI, Pastrana M, Tabernero S, Revilla J, Duran JG, Escartin P. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn’s disease: a pilot study. Inflamm Bowel Dis. 2005;11:8–15.

    Article  PubMed  Google Scholar 

  110. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn’s disease: first anniversary clinical experience. Am J Gastroenterol. 2000;95:3469–77.

    Article  CAS  PubMed  Google Scholar 

  111. Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, Peppercorn MA. Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol. 2000;95:3490–7.

    Article  CAS  PubMed  Google Scholar 

  112. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001;96:722–9.

    Article  CAS  PubMed  Google Scholar 

  113. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJH. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–405.

    Article  CAS  PubMed  Google Scholar 

  114. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–85.

    Article  CAS  PubMed  Google Scholar 

  115. Sands BE, Blank MA, Patel K, van Deventer SJ. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol. 2004;2:912–20.

    Article  CAS  PubMed  Google Scholar 

  116. Cadahia V, Garcia-Carbonero A, Vivas S, Fuentes D, Nino P, Rebollo P, Rodrigo L. Infliximab improves quality of life in the short-term in patients with fistulizing Crohn’s disease in clinical practice. Rev Esp Enferm Dig. 2004;96:369–74.

    Article  CAS  PubMed  Google Scholar 

  117. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalization, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology. 2005;128:862–9.

    Article  CAS  PubMed  Google Scholar 

  118. Agnholt J, Dahlerup JF, Buntzen S, Tøttrup A, Lyhne Nielsen S, Lundorf E. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn’s disease. Aliment Pharmacol Ther. 2003;17:703–10.

    Article  CAS  PubMed  Google Scholar 

  119. Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn’s disease. Dis Colon Rectum. 2002;45:771–5.

    Article  PubMed  Google Scholar 

  120. West RL, van der Woude CJ, Hansen BE, Felt-Bersma RJF, van Tilburg AJP, Drapers JAG, Kuipers EJ. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn’s disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20:1329–36.

    Article  CAS  PubMed  Google Scholar 

  121. Ochsenkühn T, Göke B, Sackmann M. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn’s disease. Am J Gastroenterol. 2002;97:2022–5.

    Article  PubMed  Google Scholar 

  122. Schröder O, Blumenstein I, Schulte-Buckholt A, Stein J. Combining infliximab and methotrexate in fistulizing Crohn’s disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther. 2004;19:295–301.

    Article  PubMed  CAS  Google Scholar 

  123. Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D. Infliximab in the surgical management of complex fistulating anal Crohn’s disease. Color Dis. 2005;7:164–8.

    Article  CAS  Google Scholar 

  124. Hyder SA, Travis SL, Jewell DP, Mortensen NJM, George BD. Fistulating anal Crohn’s disease: results of combined surgical and infliximab treatment. Dis Colon Rectum. 2006;49:1837–41.

    Article  PubMed  Google Scholar 

  125. Scaudione G, Di Stazio C, Limongelli P, Guadagni I, Pellino G, Riegler G, Coscione P, Selvaggi F. Treatment of complex perianal fistulas in Cohn disease: infliximab, surgery, or combined approach. Can J Surg. 2010;5:299–304.

    Google Scholar 

  126. Roumeguere P, Bouchard D, Pigot F, et al. Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohn’s disease: results from a prospective study. Inflamm Bowel Dis. 2011;17:69–76.

    Article  PubMed  Google Scholar 

  127. Tozer P, Ng SC, Siddiqui MR, et al. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn’s perianal fistulas. Inflamm Bowel Dis. 2012;18:1825–34.

    Article  PubMed  Google Scholar 

  128. Bouguen G, Siproudhis L, Gizard E, et al. Long-term outcome of perianal fistulizing Crohn’s disease treated with infliximab. Clin Gastroenterol Hepatol. 2013;11:975–81.

    Article  CAS  PubMed  Google Scholar 

  129. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119–33.

    Article  CAS  PubMed  Google Scholar 

  130. Schaible TF. Long-term safety of infliximab. Can J Gastroenterol. 2000;14:29C–32C.

    Article  PubMed  Google Scholar 

  131. Remicade (infliximab) for IV injection. Package Insert, 2002.

    Google Scholar 

  132. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–104.

    Article  CAS  PubMed  Google Scholar 

  133. Morelli J, Wilson FA. Does administration of infliximab increase susceptibility to listeriosis? Am J Gastroenterol. 2000;95:841–2.

    Article  CAS  PubMed  Google Scholar 

  134. Kamath BM, Mamula P, Baldassano RN, Markowitz JE. Listeria meningitis after treatment with infliximab. J Pediatr Gastroenterol Nutr. 2002;34:410–2.

    Article  PubMed  Google Scholar 

  135. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001;344:1099–100.

    Article  CAS  PubMed  Google Scholar 

  136. Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am J Med. 2002;112:78.

    Article  PubMed  Google Scholar 

  137. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.

    Article  CAS  PubMed  Google Scholar 

  138. Colombel JF, Scwartz DA, Sandborn WJ, Kamm MA, D’Haens G, Rutgeerts P, Enns R, Panccione R, Schreiber S, Li J, Kent JD, Lomax KG, Pollack PF. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut. 2009:940–8.

    Google Scholar 

  139. Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease. Aliment Pharmacol Ther. 2010;31:1296–309.

    Article  CAS  PubMed  Google Scholar 

  140. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomson OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, PRECiSE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357:239–50.

    Article  CAS  PubMed  Google Scholar 

  141. Schreiber S, Lawance IC, Thomson OØ, Hanauer SB, Bloomfield R, Sandborn WJ. Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease – subgroup results from a placebo-controlled trial. Aliment Pharmacol Ther. 2011;33:185–93.

    Article  CAS  PubMed  Google Scholar 

  142. Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CD, Salzberg B, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Hanauer SB. A randomized, double-blind, placebo-controlled multicenter trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn’s disease (abstr). Gastroenterology. 2000;118:A655.

    Article  Google Scholar 

  143. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR. An engineered human antibody to TNF (CDP571) for active Crohn’s disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001;120:1330–8.

    Article  CAS  PubMed  Google Scholar 

  144. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial. Gastroenterology. 1999;117:1271–7.

    Article  CAS  PubMed  Google Scholar 

  145. Vasilauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan SR. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn’s disease. Gastroenterology. 1999;117:1278–87.

    Article  Google Scholar 

  146. Erle DJ, Briskin MJ, Butcher EC, et al. Expression and function of the MAdCAM-1 receptor, integrin α4β7, on human leukocytes. J Immunol. 1994;153:517–28.

    CAS  PubMed  Google Scholar 

  147. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353:1912–25.

    Article  CAS  PubMed  Google Scholar 

  148. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353:362–8.

    Article  CAS  PubMed  Google Scholar 

  149. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–21.

    Article  CAS  PubMed  Google Scholar 

  150. Voitk AJ, Echave V, Brown RA, Gurd FN. Use of elemental during the adaptive stage of short gut syndrome. Gastroenterology. 1973;65:419–26.

    CAS  PubMed  Google Scholar 

  151. Segal AW, Levi AJ, Loewi G. Levamisole in the treatment of Crohn’s disease. Lancet. 1977;2:382–5.

    Article  CAS  PubMed  Google Scholar 

  152. Axelsson C, Jarnum S. Assessment of the therapeutic value of an elemental diet in chronic inflammatory bowel disease. Scand J Gastroenterol. 1977;12:89–95.

    CAS  PubMed  Google Scholar 

  153. Russell RI, Hall MJ. Elemental diet therapy in the management of complicated Crohn’s disease. Scott Med J. 1979;24:291–5.

    Article  CAS  PubMed  Google Scholar 

  154. Calam J, Crooks PE, Walker RJ. Elemental diets in the management of Crohn’s perianal fistulae. J Parenter Enter Nutr. 1980;4:4–8.

    Article  CAS  Google Scholar 

  155. Teahon K, Bjarnason I, Pearson M, Levi AJ. Ten years’ experience with an elemental diet in the management of Crohn’s disease. Gut. 1990;31:1133–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  156. Jones VA. Comparison of total parenteral nutrition and elemental diet in induction of remission of Crohn’s disease. Dig Dis Sci. 1987;32:100S–7S.

    Article  CAS  PubMed  Google Scholar 

  157. Fukuda Y, Kosaka T, Okui M, Hirakawa H, Shimoyama T. Efficacy of nutritional therapy for active Crohn’s disease. J Gastroenterol. 1995;30:83–7.

    Article  PubMed  Google Scholar 

  158. Harford FJ, Fazio VW. Total parenteral nutrition as primary therapy for inflammatory bowel disease of the bowel. Dis Colon Rectum. 1978;21:555–7.

    Article  PubMed  Google Scholar 

  159. Milewski PJ, Irving MH. Parenteral nutrition in Crohn’s disease. Dis Colon Rectum. 1980;23:395–400.

    Article  CAS  PubMed  Google Scholar 

  160. Greenberg GR, Fleming CR, Jeejeebhoy KN, Rosenberg IH, Sales D, Tremaine WJ. Controlled trial of bowel rest and nutritional support in the management of Crohn’s disease. Gut. 1988;29:1309–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  161. Fickert P, Hinterleitner TA, Wenzl HH, Aichbichler BW, Petritsch W. Mycopheylate mofetil in patients with Crohn’s disease. Am J Gastroenterol. 1998;93:2529–32.

    Article  CAS  PubMed  Google Scholar 

  162. Vaughan D, Drumm B. Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn’s disease. N Engl J Med. 1999;340:239–40.

    Article  CAS  PubMed  Google Scholar 

  163. Korzenik J, Dieckgraefe B. Immunostimulation in Crohn’s disease: results of a pilot study of G-CSF (R-Methug-CSF) in mucosal and fistulizing Crohn’s disease (abstr). Gastroenterology. 2000;118:A874.

    Article  Google Scholar 

  164. Dieckgraefe BK, Korzenik JR. Treatment of active Crohn’s disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet. 2002;360:1478–80.

    Article  PubMed  Google Scholar 

  165. Brady III CE, Cooley BJ, Davis JC. Healing of severe perianal and cutaneous Crohn’s disease with hyperbaric oxygen. Gastroenterology. 1989;97:756–60.

    Article  PubMed  Google Scholar 

  166. Nelson Jr EW, Bright DE, Villar LF. Closure of refractory perianal Crohn’s lesion. Integration of hyperbaric oxygen into case management. Dig Dis Sci. 1990;35:1561–6.

    Article  PubMed  Google Scholar 

  167. Brady III CE. Hyperbaric oxygen and perianal Crohn’s disease: a follow-up. Gastroenterology. 1993;105:1264.

    Article  PubMed  Google Scholar 

  168. Lavy A, Weisz G, Adir Y, Ramon Y, Melamed Y, Eidelman S. Hyperbaric oxygen for perianal Crohn’s disease. J Clin Gastroenterol. 1994;19:202–5.

    Article  CAS  PubMed  Google Scholar 

  169. Colombel JF, Mathieu D, Bouault JM, Lesage X, Zavadil P, Quandalle P, Cortot A. Hyperbaric oxygen in severe perianal Crohn’s disease. Dis Colon Rectum. 1995;38:609–14.

    Article  CAS  PubMed  Google Scholar 

  170. Oshitani N, Nakamura S, Matsumoto T, Kobayashi K, Kitano A. Treatment of Crohn’s disease fistulas with coagulation factor XIII. Lancet. 1996;347:119–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Department of Medicine, Penn Presbyterian Medical Center, University of Pennsylvania School of Medicine, 218 Wright Saunders Building, 51 N. 39th Street, Philadelphia, PA, 19104, USA

    Mark T. Osterman MD, MSCE

  2. Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, 3400 Spruce Street, Philadelphia, PA, 19104, USA

    Gary R. Lichtenstein MD

Authors
  1. Mark T. Osterman MD, MSCE
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gary R. Lichtenstein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark T. Osterman MD, MSCE .

Editor information

Editors and Affiliations

  1. Division of GI, Hepatology & Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

    Petar Mamula

  2. Division of GI, Hepatology & Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

    Andrew B. Grossman

  3. Division of GI, Hepatology & Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

    Robert N. Baldassano

  4. Division of GI, Hepatology & Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

    Judith R. Kelsen

  5. Division of Pediatric Gastroenterology & Nutrition, University of South Carolina School of Medicine - Greenville, Greenville, South Carolina, USA

    Jonathan E. Markowitz

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Osterman, M.T., Lichtenstein, G.R. (2017). Medical Treatment of Perianal Crohn’s Disease Fistulae. In: Mamula, P., Grossman, A., Baldassano, R., Kelsen, J., Markowitz, J. (eds) Pediatric Inflammatory Bowel Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-49215-5_36

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-49215-5_36

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-49213-1

  • Online ISBN: 978-3-319-49215-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation